Omzo vs MedVi: Clinician-Guided Care vs No-Clinic Semaglutide
Quick verdict: Omzo emphasizes clinician-guided, personalized compounded semaglutide and a tirzepatide option starting at $179 while MedVi emphasizes a simple online path, a promotional first month at $179 with fast, free shipping, and 24/7 certified medical support. Choose based on whether you prioritize clinician oversight and tirzepatide access or a no-clinic, promotional entry price.
Explore Omzo clinician-guided plans
Omzo vs MedVi: head-to-head on price, meds, and process
This comparison uses only supplied facts to contrast the two platforms across price structure, medication options and regulatory notes, clinical oversight and support, and user process and commitments.
1. Pricing and promotional structure
Both Omzo and MedVi show a listed entry price of $179. Omzo lists semaglutide starting at $179 and tirzepatide starting at $279. MedVi advertises a promotional first month at $179 including fast, free shipping but states the ongoing standalone month increases to $299 unless a multi-month plan is chosen. The presence of a first-month promo at MedVi and Omzo’s stated starting prices are captured as presented by each provider.
2. Medication options and regulatory notes
Omzo: supplies personalized compounded semaglutide and tirzepatide via a compounded medication program and also notes that providers may write prescriptions for branded medications which the patient must fill separately. Omzo explicitly states compounded drugs offered through its program are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality.
MedVi: provides clinically dosed compounded semaglutide only in the captured evidence and states compounded medications are produced in FDA-regulated facilities but are not FDA-approved or evaluated by the FDA for safety, efficacy, or quality. MedVi’s materials also note Wegovy and Ozempic trademarks while describing medication inclusion in program costs.
3. Clinical oversight and support
Omzo: emphasizes clinician-guided plans reviewed by licensed U.S. providers and states clinical services are provided by third party networks of U.S.-licensed clinicians who determine eligibility and make the final prescribing decision.
MedVi: emphasizes a simple online intake with no clinic visits required and 24/7 support from certified medical professionals. MedVi states OpenLoop Health clinicians or affiliated clinicians review eligibility and retain prescribing discretion after checkout.
4. Process and commitments
Omzo: connects users with licensed medical providers; it notes that the Omzo assessment does not create a doctor–patient relationship and providers determine eligibility. Medication costs appear included in fees Omzo collects and Omzo pays pharmacies, while Omzo does not sell branded medications directly.
MedVi: advertises a fully online process with no clinic visits, an intake reviewed by clinicians, medication shipped to the door, and statements that the program includes the physician review, personalized plan, 1:1 guidance and medication cost for the promotional period. MedVi also notes the first-month promo has no contract.
Comparison table: Omzo vs MedVi
| Criteria | Omzo | MedVi |
|---|---|---|
| Starting price | Semaglutide starting at $179; tirzepatide starting at $279 | Promotional first month $179 including fast, free shipping; ongoing standalone month $299 |
| Medication types offered | Compounded semaglutide & tirzepatide; providers may prescribe branded meds to fill elsewhere | Clinically dosed compounded semaglutide only (captured evidence) |
| FDA status of compounded meds | Compounded medications are not FDA-approved; not reviewed by FDA | Compounded medications produced in FDA-regulated facilities but not FDA-approved or evaluated by FDA |
| Clinical model | Clinician-guided plans reviewed by licensed U.S. providers; third-party clinician networks | Simple online intake, no clinic visits; OpenLoop Health or affiliated clinicians review and prescribe |
| Support | Clinician-guided plans (licensed providers) | 24/7 support from certified medical professionals |
Regulatory and outcome notes to keep in mind
Both providers explicitly note compounded medications are not FDA-approved and that provider discretion and clinical review determine eligibility. Omzo and MedVi caution that results vary and that individual results are not guaranteed; MedVi additionally reports some self-reported patient data in specific contexts while Omzo clarifies reported user experiences reflect internal statistics rather than public clinical trials.
Final comparison and recommendation
Omzo vs MedVi comes down to whether you want broader medication options and clinician-guided plans or a simpler, no-clinic onboarding with a first-month promotional price and 24/7 support. Omzo documents a tirzepatide option and clinician-reviewed plans plus the potential to receive a prescription for branded medications you must fill yourself. MedVi highlights an accessible first-month price of $179, fast free shipping, a fully online process with no clinic visits, and round-the-clock certified support, while noting ongoing price increases after the promo.
Choose Omzo if you want clinician-guided care with access to both compounded semaglutide and tirzepatide, and you accept that compounded medications offered are not FDA-approved and that branded prescriptions must be filled through a pharmacy.
Choose MedVi if you want the simplest online path with no clinic visits, a promotional first month at $179 including fast, free shipping, and 24/7 certified medical support, while understanding the ongoing monthly price can increase after the first month.